The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XII.f

Cardiomyopathy (acute, subacute, chronic)

Review on PMID 29858838

Publications

Brown B, Joseph C, Talanki V, Budzikowski AS, McFarlane SI, John S

Severe Hypertrophic Cardiomyopathy Associated With Hydroxychloroquine in a Young Woman With Systemic Lupus Erythematosus: A Case Report and Review of the Literature.

Cureus. 2024;16(5):e61452

Malhotra A, Pathak MA, Dalia T, Vidic A

Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis.

BMJ case reports. 2023;16(4)

Chang A, Stolin G, Fan J, Larreta BR, Fishbein GA, Wallace WD, Baas AS, Cruz D, Wang J

Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity.

ESC heart failure. 2019;6(6):1326-1330

Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM

Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.

Drug safety. 2018;41(10):919-931

Zerbib Y, Guillaumont MP, Touati G, Duhaut P, Schmidt J

[Early cardiotoxicity of Hydroxychloroquine].

La Revue de medecine interne. 2016;37(3):209-11

Tönnesmann E, Kandolf R, Lewalter T

Chloroquine cardiomyopathy - a review of the literature.

Immunopharmacology and immunotoxicology. 2013;35(3):434-42

Abbasi S, Tarter L, Farzaneh-Far R, Farzaneh-Far A

Hydroxychloroquine: a treatable cause of cardiomyopathy.

Journal of the American College of Cardiology. 2012;60(8):786

Newton-Cheh C, Lin AE, Baggish AL, Wang H

Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure.

The New England journal of medicine. 2011;364(15):1450-60

Muthukrishnan P, Roukoz H, Grafton G, Jessurun J, Colvin-Adams M

Hydroxychloroquine-induced cardiomyopathy: a case report.

Circulation. Heart failure. 2011;4(2):e7-8

Saussine A, Loriot MA, Picard C, Lecerf V, Landry J, Scheer I, Voicu S, Leenhardt A, Ducrocq G, Maubec E, Crickx B

[Chloroquine cardiotoxicity in long-term lupus therapy in two patients].

Annales de dermatologie et de venereologie. 2009;136(6-7):530-5

Manohar VA, Moder KG, Edwards WD, Klarich K

Restrictive cardiomyopathy secondary to hydroxychloroquine therapy.

The Journal of rheumatology. 2009;36(2):440-1

Soong TR, Barouch LA, Champion HC, Wigley FM, Halushka MK

New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases.

Human pathology. 2007;38(12):1858-63